• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DABIGATRAN Drug Record

  • Summary
  • Interactions
  • Claims
  • DABIGATRAN chembl:CHEMBL48361

    Alternate Names:

    PRADAXA
    BIBR-953-ZW
    DABIGATRAN
    BIBR-953

    Drug Info:

    FDA Approval approved
    Drug Class Small molecule
    Drug Indications anticoagulant
    Year of Approval 2010
    Drug Class anticoagulants
    (3 More Sources)

    Publications:

    Michaelis S et al., 2012, Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2)., J Med Chem
    Dimatteo C et al., 2016, Pharmacogenetics of dabigatran etexilate interindividual variability., Thromb Res
    Paré G et al., 2013, Genetic determinants of dabigatran plasma levels and their relation to bleeding., Circulation
    Gouin-Thibault I et al., 2017, Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin., J Thromb Haemost
    Zubiaur P et al., 2020, Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran., Adv Ther
  • DABIGATRAN   HYOU1

    Interaction Score: 13.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22494098


    Sources:
    DTC

  • DABIGATRAN   HNRNPC

    Interaction Score: 13.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22494098


    Sources:
    DTC

  • DABIGATRAN   HNMT

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22494098


    Sources:
    DTC

  • DABIGATRAN   ADK

    Interaction Score: 2.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22494098


    Sources:
    DTC

  • DABIGATRAN   CES1

    Interaction Score: 1.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27261537 23467860


    Sources:
    PharmGKB

  • DABIGATRAN   F2

    Interaction Score: 0.95

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Dabigatran
    Novel drug target Established target
    Mechanism of Interaction Thrombin inhibitor

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • DABIGATRAN   NQO2

    Interaction Score: 0.92

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22494098


    Sources:
    DTC

  • DABIGATRAN   CYP3A5

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    32564268


    Sources:
    PharmGKB

  • DABIGATRAN   ABCB1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27893182 27261537


    Sources:
    PharmGKB

  • TEND: DABIGATRAN

    • Version: 01-August-2011

    Alternate Names:
    DABIGATRAN Primary Drug Name

    Drug Info:
    Drug Class anticoagulants
    Year of Approval 2010

    Publications:

  • TdgClinicalTrial: DABIGATRAN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications anticoagulant
    Drug Class Small molecule
    FDA Approval approved

    Publications:

  • DTC: DABIGATRAN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL48361 ChEMBL Drug ID

    Drug Info:

    Publications:
    Michaelis S et al., 2012, Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2)., J Med Chem

  • PharmGKB: Dabigatran

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zubiaur P et al., 2020, Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran., Adv Ther
    Gouin-Thibault I et al., 2017, Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin., J Thromb Haemost
    Dimatteo C et al., 2016, Pharmacogenetics of dabigatran etexilate interindividual variability., Thromb Res

  • TTD: Dabigatran

    • Version: 2020.06.01

    Alternate Names:
    D0M7JT TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL48361

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL48361

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21